Abstract 397P
Background
Chronic hepatitis B infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Despite the endorsement of semi-annual ultrasonography as HCC surveillance method by international societies in at risk population, the accurate prediction of HCC risk is important for public policy strategy in a limited-resource country. Thus, we aim to develop the scoring systems, which are individualized surveillance strategy and cost-effectiveness to assess the risk of HCC in patients with chronic hepatitis B.
Methods
This retrospective cohort study was conducted to develop a risk estimate model of HCC in chronic hepatitis B (CHB) patients. Our prediction model was derived from data obtained in 2,208 CHB patients from Chulabhorn Hospital, Thailand. (Follow-up period: 2011-2017). Forward stepwise multivariable parametric regression model was applied to obtain coefficients for each predictor. Model input included age, sex, liver cirrhosis, cigarette smoking, alcohol consumption, diabetes mellitus, body mass index, serum HBV DNA level, HBeAg status, alanine aminotransferase, aspartate aminotransferase (AST), alpha-fetoprotein and AST to platelet ratio index. Receiver operating characteristic curves were used to assess discriminatory accuracy of the model.
Results
During a median follow-up of 6.67 years, 20 cases of HCC were newly diagnosed. Age and liver cirrhosis were statistical significant independent predictors of HCC risk. In the bootstrap simulation (1000 random samplings), the corrected c-index was 0.75 (0.58-0.91). The HCC risk was calculated from the following formula: Age (<50 year = 0; 50-59 year = 1; ≥ 60 year = 2) + Cirrhosis (Yes = 4; No = 0). A 6-point risk score could predict HCC risk at 10 years, ranging from 1.95%, 18.29% and 56.96% in low- (score 0-2), medium- (score 4-5) and high-risk group (score 6).
Conclusions
A simple prediction score constructed from routine clinical and laboratory parameters are accurate in predicting HCC development in Thai patients with CHB infection. Individualized HCC surveillance strategy including surveillance interval and/or alternative surveillance test could be reasonable and cost effectiveness based on our risk scoring. Future prospective validation study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Teerapat Ungtrakul.
Funding
Chulabhorn Royal Academy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract